CoChat

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people

Open access
MRC/BHF Heart Protection Study Collaborative Group · 2009 · BMC Clinical Pharmacology

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Abstract

Background: Simvastatin reduces cardiovascular mortality and morbidity but, as with other HMG-CoA reductase inhibitors, can cause significant muscle toxicity and has been associated with elevations of liver transaminases. Methods: Muscle and liver adverse effects of simvastatin 40 mg daily were evaluated in a randomized placebo-controlled trial involving 20,536 UK patients with vascular disease or diabetes (in which a substantial reduction of cardiovascular mortality and morbidity has previously been demonstrated). Results: The excess incidence of myopathy in the simvastatin group was < 0.1% over the 5 years of the trial, and there were no significant differences between the treatment groups in the incidence of serious hepatobiliary disease. Conclusion: Among the many different types of high-risk patient studied (including women, older individuals and those with low cholesterol levels), there was a very low incidence (< 0.1%) of myopathy during 5 years treatment with simvastatin 40 mg daily. The risk of hepatitis, if any, was undetectable even in this very large long-term trial. Routine monitoring of liver function tests during treatment with simvastatin 40 mg is not useful. Trial Registration: ISRCTN48489393

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1472-6904-9-6

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 73

Metadata

Authors
MRC/BHF Heart Protection Study Collaborative Group
Affiliations
University of Oxford (GB)
Corresponding author
MRC/BHF Heart Protection Study Collaborative Group
Venue
BMC Clinical Pharmacology
Published
2009-03-31
Volume
9
Issue
1
Pages
6-6
ISSN
1472-6904 (ISSN-L)
OpenAlex
W1628749699
Cited by
70
References
30
Citations by year
2025: 2 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 13 · 2013: 3 · 2012: 7
FWCI
6.42
Type
journal article
Language
en
Open access
Locations
  • BMC Clinical Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • British Heart Foundation
  • Medical Research Council (MC_EX_G0801669)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
simvastatin, myopathy, hepatotoxicity, liver transaminases, statins, statin adverse effects, long-term drug safety, vascular disease, diabetes mellitus, liver function monitoring, high-risk patients
MeSH terms
Aged, Anticholesteremic Agents, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Liver, Middle Aged, Muscles, Muscular Diseases, Patient Compliance, Placebos, Risk Factors, Incidence, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. https://app.cochat.ai/papers/10.1186/1472-6904-9-6
The paper
MRC/BHF Heart Protection Study Collaborative Group. (2009). Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clinical Pharmacology. https://doi.org/10.1186/1472-6904-9-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.